Introduction
============

Renal cell carcinoma (RCC) is a malignant tumor mainly originating from renal tubular epithelial cells, accounting for 2-3% of adult malignant tumors. Currently, the incidence rate and the mortality rate are increasing in worldwide [@B1]-[@B2]. Patients with early stage RCC have no obvious clinical symptoms, and they often have progressed to the advanced stage when obvious discomfort occurs. More specifically, RCC is a common group of chemotherapy-resistant diseases, which are not sensitive to traditional chemoradiotherapy or hormone therapy [@B3]-[@B4]. At present, the most common treatment for RCC is radical nephrectomy or nephron sparing partial nephrectomy. However, about 30% of patients have metastasized cancer when diagnosed, and about half of the patients who have not metastasized will experience recurrence or metastasis after radical resection [@B5]-[@B6].

The clear cell renal cell carcinoma (ccRCC) is the primary type of RCC, which represents 75%-80% of all RCCs [@B7]. Some studies have shown that patients with ccRCC have a poor prognosis. The 5-year survival rate of ccRCC patients is about 60%, which is lower than other types of RCC patients [@B8]-[@B9]. Currently, there are many clinical factors used to evaluate the prognosis of RCC, including histological type, Fuhrman\'s nuclear grade, tumor stage, tumor necrosis, lymph node metastasis and vein invasion. However, a single clinical factor is not ideal for predicting the prognosis of RCC [@B10]-[@B11]. Therefore, prognostic monitoring of RCC and more effective targeted therapies are essential to reduce patient mortality and improve cure rate.

There are exact evidences that the Von Hippel-Lindau (VHL) tumor suppressor gene is mutated or inactivated in more than 80% of ccRCC patients. However, in mouse (Mus musculus) experiments, it was found that the deletion of this gene did not cause the formation of clear cell carcinoma, which indicates that there are other tumorigenic mechanisms [@B12]-[@B13]. Previous studies have also found that mutations associated with renal carcinogenesis and prognosis occur mainly in genes encoding epiregulatory factors, such as the BAP1 gene that regulates histone H2A ubiquitination, the histone methyltransferase gene SETD2, and the TET2 gene which catalyzes the conversion of DNA methylation of cytosine (5mC) to 5hmC [@B14]-[@B15].

As one of the most widely studied epigenetic modifications, 5mC of the CpG dinucleotide in gene promoter is usually related to the transcriptional silencing of cancer cells [@B16]. Several important studies showed DNA methyltransferases could catalyze and maintain the transformation of cytosine to methyl cytosine, but the Ten-Eleven-Translocation (TET) family of TET1, TET2 and TET3 mediate the reverse process [@B17]-[@B19]. Gradually, these TET proteins mediate the transformation of 5mC to 5hmC, 5-formyl cytosine and 5-carboxyl cytosine [@B20].

Emerging evidence indicates that 5hmC may also act a role of stable epigenetic marker with incomplete characterization [@B21]. In our previous study, we found that almost all patients with RCC have a loss of 5hmC, which is considered to be a result of the downregulation of isocitrate dehydrogenase 1 (IDH1) [@B22]. Nevertheless, the prognostic value of 5hmC in RCC is still unclear. In present study, we attempted to define the clinical significance of 5hmC in RCC (including ccRCC and other RCC).

Material and methods
====================

Study Patients
--------------

This study contained a development cohort and a validation cohort. The development cohort included 310 RCC patients at the Department of Urology, Zhongnan Hospital of Wuhan University from January 2007 to March 2015. All patients had undergone surgery treatment meanwhile surgical tissue specimens was gathered. Dot blot assays and IHC staining of 5hmC were performed in these surgical tissue specimens. Clinical, pathological, follow-up data record was collected. The analyzed clinical and pathological data consisted of age, gender, tumor size, capsule invasion, vein invasion, tumor necrosis, TNM stage, clinical stage, Furhman grade and 5hmC level. The follow-up data included OS and CSS of RCC. All patients provided the informed consent. The Ethics Committee at Zhongnan Hospital of Wuhan University has approved the using clinical information and surgical tissue specimens in our study (approval number: 2015029). All procedures and ethical standards were done in accordance with the national research committee and/or institutional. The validation cohort was a tissue microarrays (TMA, ID: KIC387) purchased from Guilin Fanpu Biotech Co., Ltd, which included 77 RCC patients from July 2006 to October 2009.

Inclusion criteria
------------------

Patients were enrolled in this study if they met all the following criteria: (i) presence of primary RCC; (ii) without any a prior history of preoperative target therapy, chemoradiotherapy or hormone therapy; (iii) underwent radical nephrectomy or nephron sparing partial nephrectomy; (iv) surgical tissue specimens (tumor/normal) were collected; (v) had a complete and detailed clinical, pathological, follow-up data record.

Exclusion criteria
------------------

Patients meeting any of the following criteria were excluded: (i) presence of metastatic/secondary tumor of the kidney; (ii) any prior history of preoperative targeted therapy, chemoradiotherapy or hormone therapy; (iii) patients who did not undergo surgery; (iv) surgical tissue specimens were unavailable; (v) any incomplete clinical, pathological or follow-up data.

Cell lines
----------

RCC cell lines (Ketr-3, OS-RC-2, 769-P and 786-O) were cultured in RPMI1640 medium (Gibco, China) supplemented with 10% FBS. Human renal proximal tubular epithelial cell line (HK-2) was maintained in KSF medium with epidermal growth factor as well as bovine pituitary extract (Gibco, Carlsbad, CA, USA). All cell lines were purchased from the Stem Cell Bank, Chinese Academy of Sciences in Shanghai, China. These cell lines were grown at 5% CO~2~, 37℃ in a humidified incubator (Thermo Scientific).

Cell lines and tissue genomic DNA extraction
--------------------------------------------

A proportion of the surgical tissue specimens were cryopreserved at -80℃. We used tumor as well as the matched normal tissue from the same radical nephrectomy patients for DNA analysis. Genomic DNA was isolated from cultured RCC cell lines and surgical tissue specimens with the Qiagen DNA Mini Kit (250) (Qiagen, Cat\#: 51306).

Quantitative 5hmC analysis
--------------------------

Quantitative 5hmC analysis performed via DNA dot blotting. Genomic DNA was heated for deformation and then chilled; temperature/time were 95℃/10min and 4℃/5min, respectively. The DNA samples were dried on wet Hybrid Membrane. The samples were then spotted on positively charged membranes and afterwards serially diluted in NaOH/EDTA solution. The membrane was blocked with 5% non-fat milk in TBST for 1 h at room temperature (RT), followed by incubation with primary antibody against 5hmC (dilution 1:5000, Active motif) overnight at 4℃. Anti-rabbit IgG-HRP antibody was incubated with the membrane for 1 h at RT. At last, the membrane was treated with ECL Kit (GE Amersham, Cat\#: RPN2232) after washing three times with TBST.

Immunohistochemical staining and scoring
----------------------------------------

A proportion of surgical tissue specimens were fixed with formalin to for paraffin-embedded. IHC analyses was performed on 4 μm thick sections. Briefly, each slide was incubated with primary antibody against 5hmC (1: 5000, Active motif, Cat\#: 39999) overnight after a series of procedures (de-paraffin, antigen retrieval, rinse). This was followed by an incubation with the anti-rabbit IgG-HRP antibody (EnVision Dual Link, Dako) for 30 min. The membrane was then washed five times with TBST and enriched with the brown color of DAB Enhancer (Dako). The 5hmC expression was evaluated by three experienced pathologists. Receiver operating characteristic (ROC) curve was generated for 5hmC expression level to calculate the areas under the curve (AUC). The highest Youden\'s index, as the optimized point, was used to determine the optimal cut-off value of 5hmC expression level based on the ROC curve.

Statistical analysis
--------------------

All continuous measures were compared by two-sample *t* test, graded variables were analyzed with Mann-Whitney test. The associations between 5hmC expression level and specific clinicopathological factors in RCC patients (including ccRCC and other RCC) were analyzed with Chi-square test. Kaplan-Meier curves were generated to estimate OS and CSS, and the log-rank test was used to assess survival differences among subgroups. Cox univariate and multivariate survival analyses were used to estimate the independent factors of survival rate. Nomograms were generated based on cox regression analyses. The calibration curves were generated to assess the agreements of the nomogram-predicted probability with the actual observed probability. The stability (sensitivity and specificity) of the prediction nomograms were validated with the independent external cohort. We used SPSS 16.0 and GraphPad Prism 7 to perform all statistical analyses. Nomograms and calibration curves were generated with R version 3.5.0 and a p value \<0.05 was considered statistically significant.

Results
=======

5hmC level was significantly decreased in RCC
---------------------------------------------

To detect the change of 5hmC level in RCC tumorigenesis, we performed DNA dot blot assay using RCC and normal counterparts. The results showed 5hmC was downregulated in 3 RCC tumor samples compared with the matched normal tissues. RCC cell lines also yielded similar results, in which human renal proximal tubular epithelial cell line (HK-2) expressed highest level of 5hmC compared with all four RCC cell lines (Figure [1](#F1){ref-type="fig"}A). In the following study, we performed IHC staining in RCC and normal kidney tissues adjacent to cancer. IHC staining presented that 5hmC level in 310 RCC patients\' tumor tissues was significantly downregulated as compared with that in 248 adjacent kidney tissues (Figure [1](#F1){ref-type="fig"}B, 1C). With the method mentioned, the cut-off value of 5hmC relative expression level was determined as 20.4% (AUC=0.836, Supplementary [Figure S1](#SM0){ref-type="supplementary-material"}). So "5hmC low" and "5hmC high" represented cases in which ≤20% and \>20% cells were positive for IHC staining of 5hmC, respectively (Figure [1](#F1){ref-type="fig"}D).

Patient characteristics
-----------------------

Of 310 RCC patients, those diagnosed with ccRCC were accounted for 230 (74.2%). The median follow-up time was 90.9 months (range 0.3-122.4 months) for all patients. Additionally, 215 (69.4%) patients were followed up for more than 5 years, and 111 (35.8%) patients more than 10 years. During follow-up, 135 (43.5%) patients died and the 5-year and 10-year OS rates were 70.6% and 56.5%, respectively. Table [1](#T1){ref-type="table"} listed the clinicopathological parameters (gender, age, tumor size, capsule invasion, vein invasion, tumor necrosis, TNM stage, clinical stage, Furhman grade and 5hmC level). Briefly, 114 female and 196 male patients with a mean age of 61.8 y (25-87 y). 168 patients identified as were "5hmC low" and 142 were "5hmC high". Two-sample *t* test and standard nonparametric Mann-Whitney *U*-test showed ccRCC patients in 5hmC low group with a higher clinical stage, higher T stage, lower Furhman grade, compared with 5hmC high group RCC patients (p\<0.05, Table [1](#T1){ref-type="table"}).

Of 77 RCC patients in the validation cohort, 59 (76.6%) patients were diagnosed with ccRCC. The median follow-up time was 82.1 months (range 1.1-133.6 months). The detailed clinical parameters of enrolled patients in development cohort and validation cohort were presented in Supplementary [Table s1](#SM0){ref-type="supplementary-material"}, there was no significant difference in clinical parameters between the two cohorts (all p\>0.05).

Correlation analysis between 5hmC expression level and clinicopathological factors of patients with RCC
-------------------------------------------------------------------------------------------------------

The correlations between 5hmC and clinicopathological factors were analyzed to define the clinical significance of 5hmC in RCC. Chi-square testing showed that there were no significant correlations between 5hmC level and age, gender, tumor necrosis, N stage, or Furhman grade (Table [2](#T2){ref-type="table"}). Remarkably, we found 5hmC level was significantly correlated with tumor size, capsule invasion, vein invasion, T stage, M stage and clinical stage with p values of 0.011, 0.001, 0.012, 0.003, 0.002, 0.001, respectively. Interestingly, these differences were mainly concentrated in other RCC and 5hmC did not seem to affect these clinicopathological variables in ccRCC patients (Table [2](#T2){ref-type="table"}). In the validation cohort, chi-square testing also showed the consistent results, which validated our finding (Supplementary [Table s2](#SM0){ref-type="supplementary-material"}).

Kaplan-Meier survival analysis between 5hmC expression level and patient survival
---------------------------------------------------------------------------------

In the Kaplan-Meier survival analyses, compared to those RCC patients with low 5hmC, patients with high 5hmC had increased OS and CSS (Log-rank, p=0.0054, p\<0.0001, respectively, Figure [2](#F2){ref-type="fig"}A). This finding indicated that high 5hmC expression led to a good prognostic impact for RCC patients. Similar results were also yielded in ccRCC patients (Figure [2](#F2){ref-type="fig"}B) and other RCC patients (Figure [2](#F2){ref-type="fig"}C).

Cox univariate and multivariate analyses of patient survival
------------------------------------------------------------

Cox univariate and multivariate survival analyses were performed to assess the prognostic value of 5hmC level for RCC and ccRCC patients. Univariate survival analysis showed age, tumor size, capsule invasion, vein invasion, TNM stage, clinical stage, Furhman grade and 5hmC level were factors significantly affecting RCC patient OS. Tumor size, capsule invasion, vein invasion, TNM stage, clinical stage, Furhman grade and 5hmC level were factors significantly affecting CSS. Moreover, multivariate survival analyses revealed that age (HR: 1.043; 95%CI: 1.027-1.059; p\<0.001), capsule invasion (HR: 1.745; 95%CI: 1.059-2.877; p=0.029), N stage (HR: 3.110; 95%CI: 1.491-6.485; p=0.002), clinical stage (HR: 1.334; 95%CI: 1.050-1.695; p=0.018), Furhman grade (HR: 1.508; 95%CI: 1.238-1.837; p\<0.001) and 5hmC level (HR: 0.657; 95%CI: 0.455-0.949; p=0.025) were independent prognostic factors for RCC patient OS, but only clinical stage (HR: 2.381; 95%CI: 1.892-2.996; p\<0.001), Furhman grade (HR: 1.740; 95%CI: 1.325-2.285; p\<0.001) and 5hmC level (HR: 0.404; 95%CI: 0.231-0.709; p=0.002) were the independent prognostic factors for RCC patient CSS (Table [3](#T3){ref-type="table"}, Table [4](#T4){ref-type="table"}, respectively).

The effect of 5hmC in prognosis of ccRCC, the major subtype of RCC, were also of interest. Univariate and multivariate survival analyses revealed that age (HR: 1.042; 95%CI: 1.023-1.061; p\<0.001), N stage (HR: 2.176; 95%CI: 0.989-4.786; p=0.053), clinical stage (HR: 1.537; 95%CI: 1.257-1.880; p\<0.001) and Furhman grade (HR: 1.349; 95%CI: 1.068-1.703; p=0.012) were independent prognostic factors for ccRCC patient OS, but vein invasion (HR: 2.273; 95%CI: 1.187-4.351; p=0.013), clinical stage (HR: 1.940; 95%CI: 1.385-2.718; p\<0.001), Furhman grade (HR: 1.661; 95%CI: 1.179-2.339; p=0.004) and 5hmC level (HR: 0.381; 95%CI: 0.188-0.774; p=0.008) were the independent prognostic factors for ccRCC patient CSS (Table [5](#T5){ref-type="table"}, Table [6](#T6){ref-type="table"}).

These results suggested that 5hmC level could be considered as an important prognostic biomarker for both RCC and ccRCC.

Construction of nomogram to predict survival probability
--------------------------------------------------------

Based on our cox regression analyses, nomograms were constructed to calculate each RCC patient survival probability directly. The 10-year OS (Figure [3](#F3){ref-type="fig"}A) and CSS (Figure [3](#F3){ref-type="fig"}B) probabilities of RCC patients were able to be accurately calculated via the nomograms according to the information of each patient (5hmC, age, capsule invasion, N stage, clinical stage, Furhman grade). The calibration curves displayed good agreements of the nomogram-predicted probability with the actual probability for OS (Figure [3](#F3){ref-type="fig"}C) and CSS (Figure [3](#F3){ref-type="fig"}D), which indicated that these nomograms had a great value of prediction. Figure [4](#F4){ref-type="fig"}A and [4](#F4){ref-type="fig"}B were the nomograms of ccRCC patient 10-year OS and CSS, respectively. The calibration curves shown in Figure [4](#F4){ref-type="fig"}C and [4](#F4){ref-type="fig"}D, also displayed good agreement.

External validation for the prediction nomograms
------------------------------------------------

To confirm the stability of the prediction nomograms, external data validations were performed, which was independently collected in another center (TMA). For 10-year OS prediction of RCC, the sensitivity was 77.3% and the specificity was 81.8%; for 10-year OS prediction of ccRCC, the sensitivity was 76.7% and the specificity was 82.8% (Supplementary [Table s3](#SM0){ref-type="supplementary-material"}-s4).

Taken together, the results well validated the main findings, the prediction nomograms exhibit high accuracy and stability and are well generalized for other independent datasets.

Discussion
==========

As a mature epigenetic abnormal change, suppression of 5mC is a common DNA modification in human malignant tumors. It therefore has great potential as a kind of cancer treatment target [@B16], [@B23]-[@B24]. Accumulating evidence suggests that 5hmC confers unique epigenetics, and it can play an important role in multiple tumors, such as liver cancer, melanoma, and acute myeloid leukemia [@B25]-[@B28]. In this study, both dot blot and IHC indicated that 5hmC was significantly decreased in RCC compared with those in their normal tissue counterparts. Kaplan-Meier curves revealed that high 5hmC level led to good prognostic impact for RCC patients. Our study established 5hmC loss as a probably common epigenetic characteristic in human tumors including RCC, as with the other reports [@B25]-[@B28]. For this reason, we proposed that 5hmC loss might correlated with kidney tumorigenesis and then investigated.

Numerous studies have shown that the loss of 5hmC is associated with the cancer aggressiveness [@B25]-[@B26]. In gastric cancer, a decrease in 5hmC promoted the metastasis of gastric cancer cells. Furthermore, suppression of 5hmC was more likely to be present in high grade pathological and large volume tumors in gliomas. In the melanoma, glioma, and esophageal squamous cell carcinoma, the reduction of 5hmC was shown to be an epigenetic hallmark [@B29]-[@B31]. However, the prognostic value of 5hmC in renal cell carcinoma (RCC) is still unclear.

This study indicated that low 5hmC level was significantly associated with tumor size, capsule invasion, vein invasion, T stage, M stage, clinical stage, shorter OS and CSS in our RCC patient cohort. Furthermore, Kaplan-Meier curves revealed that the high 5hmC expression had a good prognostic impact in RCC patients. More importantly, cox univariate and multivariate survival analyses further indicated 5hmC was independent prognostic factor for RCC affecting patient survival. These findings suggested that 5hmC might have great values of prognostic in RCC patients.

In recent years, nomogram has been widely used in clinical research modeling. It transforms the complex cox regression survival analyses into a simple and visualized graph, which makes the results of the prediction model more readable and has higher application value. The advantage makes the nomograms get more attention and application in medical research and clinical practice. With the 10-year follow-up data of 310 RCC patients, we developed nomograms to calculate RCC survival probability for the first time. The calibration curves displayed good agreements, which showed nomograms had a great value of prediction. The nomograms may be used to calculate the 10-year OS and CSS probabilities of RCC patients accurately according to the information of each patient. Therefore, clinicians can use these nomograms to make the treatment planning and patient-clinician communication. In addition, our findings were validated with an independent external cohort included 77 RCC cases. The prediction nomograms exhibit high accuracy and stability and are well generalized for other independent datasets.

Of course, considering the effect of racial/ethnic differences and the limitation of small amount of data, multiple center data and more cases are needed for further study.

Conclusion
==========

5hmC was significantly downregulated in RCC patients. The level of 5hmC was significantly correlated with capsule invasion, vein invasion, T stage, M stage and clinical stage. High 5hmC level led to good prognostic impact for RCC patients and 5hmC was independent prognostic factor in RCC patient survival. In order to establish 5hmC as a novel biomarker for RCC in future, more investigations of its expression, function and regulation are warranted.
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![**Relative expression of 5hmC in RCC (A)** Dot blot assays of 5hmC in RCC cell lines/HK-2 as well as paired RCC tissues/renal tissues of three RCC patients. Equal loading was validated by methylene blue staining. T, tumor; N, matched normal tissue; **(B)** A representative IHC staining of 5hmC in tumor and paired normal samples of RCC patients. Scare bar, 200 μm; **(C)** Relative expression of 5hmC level in RCC (include ccRCC and other RCC) tissues/renal tissues; **(D)** A representative IHC staining of "5hmC low" RCC tissue and "5hmC high" RCC tissue. "5hmC low" and "5hmC high" represented cases in which ≤20% and \>20% cells were positive for IHC staining of 5hmC, respectively. Scare bar, 200 μm.](jcav11p1212g001){#F1}

![**Kaplan-Meier survival (OS and CSS) curves of RCC patients (A)** RCC patients; **(B)** ccRCC patients;**(C)** other RCC patients. "5hmC low" and "5hmC high" represented cases in which ≤20% and \>20% cells were positive for IHC staining of 5hmC, respectively. P values were calculated with the log-rank test.](jcav11p1212g002){#F2}

![**The predicted nomograms and calibration curves of RCC patient survival (A)** the nomogram developed for OS among 310 RCC patients; **(B)** the nomogram developed for CSS among 310 RCC patients;**(C)** The calibration curve developed for OS among 310 RCC patients;**(D)** The calibration curve developed for CSS among 310 RCC patients. For the nomogram, the points for each variable were calculated by drawing a straight line from a variable value to the axis labelled "Points". The score sum was converted to a probability in the lowest axis.](jcav11p1212g003){#F3}

![**The predicted nomograms and calibration curves of ccRCC patient survival (A)** The nomogram developed of OS among 230 ccRCC patients; **(B)** The nomogram developed for CSS among 230 ccRCC patients;**(C)** The calibration curve developed for OS among 230 ccRCC patients;**(D)** The calibration curve developed for CSS among 230 ccRCC patients. In the nomogram, the points for each variable were calculated by drawing a straight line from a patient\'s variable value to the axis labelled "Points". The score sum was converted to a probability in the lowest axis.](jcav11p1212g004){#F4}

###### 

Clinical characteristics of ccRCC and other RCC patients.

  --------------------------------------------------------------------------------------
  Variables                     RCC\           ccRCC\         other RCC\     *p* value
                                (n=310)        (n=230)        (n = 80)       
  ----------------------------- -------------- -------------- -------------- -----------
  **Age (years), n (%)**                                                     0.156

  Average/Median                61.8±13.5/64   61.3±13.5/63   63.5±13.5/66   

  Range                         25-87          25-87          28-87          

  \< 65                         161 (51.9)     125 (54.3)     36 (45.0)      

  ≥ 65                          149 (48.1)     105 (45.7)     44 (55.0)      

  **Gender, n (%)**                                                          0.234

  Female                        114 (36.8)     89 (38.7)      25 (31.2)      

  Male                          196 (63.2)     141 (61.3)     55 (68.8)      

  **Tumor Size (cm), n (%)**                                                 0.771

  Average/Median                6.2±3.7/5.0    6.1±3.6/5.0    6.4±4.1/5.0    

  Range                         0.5-23.0       0.9-23.0       0.5-18.0       

  ≤ 5                           159 (51.3)     115 (50.0)     44 (55.0)      

  \> 5                          151 (48.7)     115 (50.0)     36 (45.0)      

  **Capsule Invasion, n (%)**                                                0.097

  No                            226 (72.9)     162 (70.4)     64 (80.0)      

  Yes                           84 (27.1)      68 (29.6)      16 (20.0)      

  **Vein Invasion, n (%)**                                                   0.187

  No                            252 (81.3)     183 (79.6)     69 (86.2)      

  Yes                           58 (18.7)      47 (20.4)      11 (13.8)      

  **Necrosis, n (%)**                                                        0.044

  No                            281 (90.6)     213 (92.6)     68 (85.0)      

  Yes                           29 (9.4)       17 (7.4)       12 (15.0)      

  **T Stage, n (%)**                                                         0.035

  T1                            179 (57.7)     125 (54.3)     54 (67.5)      

  T2                            25 (8.1)       18 (7.8)       7 (8.8)        

  T3                            102 (32.9)     85 (37.0)      17 (21.2)      

  T4                            4 (1.3)        2 (0.9)        2 (2.5)        

  **N Stage, n (%)**                                                         0.461

  N0/Nx                         298 (96.1)     220 (95.7)     78 (97.5)      

  N1                            6 (1.9)        5 (2.2)        1 (1.3)        

  N2                            6 (1.9)        5 (2.2)        1 (1.3)        

  **M Stage, n (%)**                                                         0.871

  M0/Mx                         288 (92.9)     214 (93.0)     74 (92.5)      

  M1                            22 (7.1)       16 (7.0)       6 (7.5)        

  **Clinical Stage, n (%)**                                                  0.026

  1                             175 (56.5)     121 (52.6)     54 (67.5)      

  2                             25 (8.1)       18 (7.8)       7 (8.8)        

  3                             85 (27.4)      73 (31.7)      12 (15.0)      

  4                             25 (8.1)       18 (7.8)       7 (8.8)        

  **Furhman Grade, n (%)**                                                   \<0.001

  1                             64 (20.6)      62 (27.0)      2 (2.5)        

  2                             122 (39.4)     90 (39.1)      32 (40.0)      

  3                             89 (28.7)      62 (27.0)      27 (33.8)      

  4                             35 (11.3)      16 (7.0)       19 (23.8)      

  **5hmC%, n (%)**                                                           \<0.001

  Average/Median                28.2±25.0/20   23.8±21.3/20   40.7±30.2/40   

  Range                         0-23.0         0-90           1-100          

  Low (≤20%)                    168 (54.2)     140 (60.9)     28 (35.0)      

  High (\>20%)                  142 (45.8)     90 (39.1)      52 (75.0)      
  --------------------------------------------------------------------------------------

###### 

Correlations between 5hmC expression and clinicopathological factors of patients with RCC and ccRCC.

  Characteristics       5hmC expression (RCC)   5hmC expression (ccRCC)   5hmC expression (other RCC)                                
  --------------------- ----------------------- ------------------------- ----------------------------- ----- ---- ------- ---- ---- ---------
  Age (years), n                                                          0.864                                    0.804             0.451
  \< 65                 88                      73                                                      77    48           11   25   
  ≥ 65                  80                      69                                                      63    42           17   27   
  Gender, n                                                               0.959                                    0.546             0.527
  Female                62                      52                                                      52    37           10   15   
  Male                  106                     90                                                      88    53           18   37   
  Tumor Size (cm), n                                                      0.011                                    0.177             0.011
  ≤ 5                   75                      84                                                      65    50           10   34   
  \> 5                  93                      58                                                      75    40           18   18   
  Capsule Invasion, n                                                     0.001                                    0.285             \<0.001
  No                    110                     116                                                     95    67           15   49   
  Yes                   58                      26                                                      45    23           13   3    
  Vein Invasion, n                                                        0.012                                    0.141             0.071
  No                    128                     124                                                     107   76           21   48   
  Yes                   40                      18                                                      33    14           7    4    
  Necrosis, n                                                             0.779                                    0.394             0.646
  No                    153                     128                                                     128   85           25   43   
  Yes                   15                      14                                                      12    5            3    9    
  T Stage, n                                                              0.003                                    0.260             \<0.001
  T1-T2                 98                      106                                                     83    60           15   46   
  T3-T4                 70                      36                                                      57    30           13   6    
  N Stage, n                                                              0.140                                    0.349             0.580
  N0/Nx                 159                     139                                                     132   88           27   51   
  N1-N2                 9                       3                                                       8     2            1    1    
  M Stage, n                                                              0.002                                    0.024             0.018
  M0/Mx                 149                     139                                                     126   88           23   51   
  M1                    19                      3                                                       14    2            5    1    
  Clinical Stage, n                                                       0.001                                    0.121             \<0.001
  1-2                   94                      106                                                     79    60           15   46   
  3-4                   74                      36                                                      61    30           13   6    
  Furhman Grade, n                                                        0.094                                    0.479             0.602
  1-2                   108                     78                                                      95    57           13   21   
  3-4                   60                      64                                                      45    33           15   31   

###### 

Cox univariate and multivariate analyses of overall survival among 310 RCC patients.

  RCC patients (n = 310)      Univariate analysis   Multivariate analysis                                      
  --------------------------- --------------------- ----------------------- ---------- ------- --------------- ----------
  Gender (F/M)                1.082                 0.760 - 1.539           0.662      \-      \-              \-
  Age (years)                 1.043                 1.027 - 1.059           \< 0.001   1.043   1.027 - 1.059   \< 0.001
  Tumor Size (cm)             1.104                 1.060 - 1.150           \< 0.001   1.020   0.966 - 1.078   0.477
  Capsule Invasion (yes/no)   3.187                 2.260 - 4.494           \< 0.001   1.745   1.059 - 2.877   0.029
  Vein Invasion (yes/no)      2.840                 1.958 - 4.120           \< 0.001   1.364   0.788 - 2.362   0.268
  Necrosis (yes/no)           1.588                 0.941 - 2.680           0.083      \-      \-              \-
  T Stage (T3-T4 vs. T1-T2)   3.368                 2.396 - 4.734           \< 0.001   1.504   0.497 - 3.271   0.760
  N Stage (N1-N2 vs. N0/Nx)   4.914                 2.626 - 9.198           \< 0.001   3.110   1.491 - 6.485   0.002
  M Stage (M1 vs. M0/Mx)      4.224                 2.584 - 6.904           \< 0.001   1.537   0.670 - 3.523   0.310
  Clinical Stage              1.783                 1.526 - 2.082           \< 0.001   1.334   1.050 - 1.695   0.018
  Furhman Grade               1.475                 1.228 - 1.771           \< 0.001   1.508   1.238 - 1.837   \< 0.001
  5hmC (high/low)             0.624                 0.441 - 0.884           0.008      0.657   0.455 - 0.949   0.025

###### 

Cox univariate and multivariate analyses of cancer specific survival among 310 RCC patients.

  RCC patients (n = 310)      Univariate analysis   Multivariate analysis                                      
  --------------------------- --------------------- ----------------------- ---------- ------- --------------- ----------
  Gender (F/M)                1.069                 0.657 - 1.740           0.788      \-      \-              \-
  Age (years)                 1.013                 0.995 - 1.032           0.163      \-      \-              \-
  Tumor Size (cm)             1.166                 1.111 - 1.224           \< 0.001   1.002   0.935 - 1.073   0.961
  Capsule Invasion (yes/no)   5.553                 3.449 - 8.941           \< 0.001   1.527   0.706 - 3.302   0.282
  Vein Invasion (yes/no)      5.662                 3.543 - 9.049           \< 0.001   1.427   0.736 - 2.764   0.292
  Necrosis (yes/no)           1.571                 0.779 - 3.165           0.207      \-      \-              \-
  T Stage (T3-T4 vs. T1-T2)   7.577                 4.469 - 12.847          \< 0.001   1.736   0.339 - 8.883   0.508
  N Stage (N1-N2 vs. N0/Nx)   7.195                 3.650 - 14.184          \< 0.001   2.077   0.957 - 4.508   0.064
  M Stage (M1 vs. M0/Mx)      6.954                 4.001 - 12.088          \< 0.001   1.247   0.460 - 3.380   0.665
  Clinical Stage              2.693                 2.138 - 3.392           \< 0.001   2.381   1.892 - 2.996   \< 0.001
  Furhman Grade               1.708                 1.328 - 2.197           \< 0.001   1.740   1.325 - 2.285   \< 0.001
  5hmC (high/low)             0.355                 0.208 - 0.606           \< 0.001   0.404   0.231 - 0.709   0.002

###### 

Cox univariate and multivariate analyses of overall survival among 230 ccRCC patients.

  ccRCC patients (n = 230)    Univariate analysis   Multivariate analysis                                      
  --------------------------- --------------------- ----------------------- ---------- ------- --------------- ----------
  Gender (F/M)                1.058                 0.702 - 1.594           0.788      \-      \-              \-
  Age (years)                 1.044                 1.026 - 1.063           \< 0.001   1.042   1.023 - 1.061   \< 0.001
  Tumor Size (cm)             1.092                 1.039 - 1.148           0.001      1.016   0.930 - 1.366   0.900
  Capsule Invasion (yes/no)   2.886                 1.928 - 4.320           \< 0.001   1.723   0.865 - 4.168   0.274
  Vein Invasion (yes/no)      2.747                 1.788 - 4.221           \< 0.001   1.700   0.899 - 3.217   0.103
  Necrosis (yes/no)           2.010                 1.040 - 3.885           0.038      1.153   0.584 - 2.276   0.682
  T Stage (T3-T4 vs. T1-T2)   3.070                 2.052 - 4.593           \< 0.001   1.246   0.790 - 3.016   0.282
  N Stage (N1-N2 vs. N0/Nx)   5.112                 2.543 - 10.276          \< 0.001   2.176   0.989 - 4.786   0.053
  M Stage (M1 vs. M0/Mx)      3.886                 2.155 - 7.009           \< 0.001   1.327   0.478 - 3.686   0.587
  Clinical Stage              1.749                 1.450 - 2.109           \< 0.001   1.537   1.257 - 1.880   \< 0.001
  Furhman Grade               1.456                 1.167 - 1.816           0.001      1.349   1.068 - 1.703   0.012
  5hmC (high/low)             0.658                 0.430 - 1.009           0.055      0.724   0.462 - 1.133   0.158

###### 

Cox univariate and multivariate analyses of cancer specific survival among 230 ccRCC patients.

  ccRCC patients (n = 230)    Univariate analysis   Multivariate analysis                                      
  --------------------------- --------------------- ----------------------- ---------- ------- --------------- ----------
  Gender (F/M)                1.228                 0.684 - 2.204           0.493      \-      \-              \-
  Age (years)                 1.012                 0.991 - 1.034           0.269      \-      \-              \-
  Tumor Size (cm)             1.142                 1.074 - 1.214           \< 0.001   1.072   0.895 - 1.455   0.497
  Capsule Invasion (yes/no)   4.166                 2.377 - 7.302           \< 0.001   1.390   0.914 - 4.633   0.146
  Vein Invasion (yes/no)      5.811                 3.326 - 10.155          \< 0.001   2.273   1.187 - 4.351   0.013
  Necrosis (yes/no)           1.680                 0.665 - 4.247           0.273      \-      \-              \-
  T Stage (T3-T4 vs. T1-T2)   5.735                 3.086 - 10.658          \< 0.001   1.163   0.742 - 3.472   0.876
  N Stage (N1-N2 vs. N0/Nx)   7.653                 3.544 - 16.525          \< 0.001   2.203   0.893 - 5.434   0.086
  M Stage (M1 vs. M0/Mx)      6.206                 3.153 - 12.216          \< 0.001   2.129   0.645 - 7.026   0.215
  Clinical Stage              2.464                 1.859 - 3.265           \< 0.001   1.940   1.385 - 2.718   \< 0.001
  Furhman Grade               1.601                 1.183 - 2.169           0.002      1.661   1.179 - 2.339   0.004
  5hmC (high/low)             0.405                 0.207 - 0.791           0.008      0.381   0.188 - 0.774   0.008
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